

FIGURE 1





FIGURE 2



# FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8






FIGURE 9





FIGURE 10



# FIGURE 11




FIGURE 12





FIGURE 13



# FIGURE 14




FIGURE 15







FIGURE 16





# FIGURE 17




FIGURE 18




FIGURE 19







FIGURE 20



# FIGURE 21



## Amprenavir (Agenerase™)

## REP 2003





## Indinavir (Crixivan™)

## REP 2004



## Lopinavir (Kaletra™)

## REP 2006



## Saquinavir (Fortovase™)

## REP 2007





FIGURE 22

a

Drug	IC50 (uM)
REP 2003	4.01
REP 2004	0.065
REP 2006	0.014
REP 2007	0.015
Amprenavir	0.016
Indinavir	0.006
Lopinavir	0.004
Saquinavir	0.003




FIGURE 23




FIGURE 24

Drug	IC50 (uM)		Fold change in IC50
	HIV-1 NL4-3	HIV-1 MRDC4	
REP 2003	4.01	3.69	0.92
REP 2004	0.065	0.046	0.71
REP 2006	0.014	0.014	1.00
REP 2007	0.015	0.013	0.87
Amprenavir	0.017	0.065	3.82
Indinavir	0.006	0.08	13.33
Lopinavir	0.004	0.096	24.00
Saquinavir	0.003	0.006	2.00



# FIGURE 25




FIGURE 26






FIGURE 27



# FIGURE 28






FIGURE 29

a



b



c




FIGURE 30




FIGURE 31




FIGURE 32







FIGURE 33




FIGURE 34




FIGURE 35




FIGURE 36




FIGURE 37

